Abstract
CD105 is an auxiliary receptor for the Transforming Growth Factor Beta superfamily, highly expressed on proliferating endothelial cells and adult hematopoietic stem cells. Because CD105 mRNA expression was reported in the developing aortic region, we further characterized its expression profile in the aorta and examined the hematopoietic potential of CD105 + cells.
Aortic endothelial cells, intra-aortic hematopoietic cells clusters and the purified cell fraction enriched in progenitor/hematopoietic stem cell activity expressed CD105. Aortic hematopoietic short-term clonogenic progenitors were highly enriched in the CD105 intermediate population whereas more immature long-term progenitors/hematopoietic stem cells are contained within the CD105 high population.
This places CD105 in the short list of molecules discriminating short-term vs longterm progenitors in the aorta. Moreover decreasing Transforming Growth Factor Beta signaling increases the number of clonogenic progenitors. This suggests that CD105 expression level defines a hierarchy among aortic hematopoietic cells allowing purification of clonogenic versus more immature hematopoietic progenitors, and that the Transforming Growth Factor Beta pathway plays a critical role in this process.
Introduction
The aorta-gonad-mesonephros (AGM) region at embryonic day 10.5 (E10.5) was shown to produce a cohort of hematopoietic cells composed of short-and longterm Hematopoietic Progenitors (HPs) as well as Hematopoietic Stem Cells (HSCs).(1) Much effort has been devoted to the identification and purification of the different sub-categories of AGM-derived Hematopoietic Cells (HCs) but so far no simple marker allows discriminating short-term committed versus long term HP/HSC. In addition, little is known about the signaling pathways controlling AGM-derived HP/HSC emergence, survival and proliferation. Multiple lines of evidence support a role for CD105/endoglin in blood and vascular development. CD105 is an ancillary receptor for members of the Transforming Growth Factor ßeta (TGFß) superfamily including TGFß1/3, Activin and Bone Morphogentic Proteins 2/7.(2) CD105 is expressed at the surface of Endothelial Cells (ECs)(3) and adult bone marrow HSCs, (4, 5) being part of the markers identifying adult long-term repopulating HSCs and defining discrete subsets in the erythromyeloid lineage.(6) Besides its role in cardiovascular development, CD105 was shown to be essential for hematopoietic commitment from the hemangioblast (7, 8) and implicated in embryonic hematopoiesis. (9) We thus further characterized CD105 expression during AGM hematopoiesis. At E11, CD105 was expressed on endothelial and intra-aortic hematopoietic cell clusters containing long-term HPs/HSCs. 
Design and Methods

Animals and tissue preparation
Embryos were generated from C57BL/6 mice. Day 0 is day of vaginal plugging (E0). AGMs were dissected and dissociated as previously described.(10)
Human embryos
Human embryonic tissues were obtained following voluntary, spontaneous or therapeutic abortions. Informed consent for the use of the embryo in research was obtained from the patient, and tissue collection and use were performed according to the guidelines and with the approval of the French National Ethic Committee. Developmental age was estimated as previously described. (11) Immunostaining and flow-cytometric analysis Embryos were processed as previously described. (12) Frozen sections (10 µm) were cut on a cryostat (Leica). Anti-mouse CD105-PE (1/50) and CD105 (1/100)(Biolegend), anti-human CD105 (1/40, R&D), anti-mouse CD31 (1/100), antimouse CD144 (11D4, 1/50, BD) and anti-IgG Rat-HRP (1/100, BD) antibodies were used for immunostaining followed by TSA amplification (Perkin Elmer). Nuclei were labeled with DAPI 1/1000 (Sigma). Anti-CD105-PE, CD144-Alexa647 (BV13, eBiosciences), CD34-FITC, CD41-FITC, CD45-FITC, c-kit-APC (BD) were used for flow cytometry. Cells were sorted on an Influx 500 cell sorter (Cytopeia, BD Biosciences) or a FACSDiva cell sorter (BD Biosciences). Analysis was performed on a MoFlo (Beckman-Coulter).
RT-PCR
Total RNA was prepared from 10x10 3 sorted cells using Trizol reagent. To avoid genomic contamination, RNA samples were treated with RNAse-free DNAse I. Oligo-dT primers and reverse transcriptase (SuperscriptII) were used for cDNA synthesis. All reagents are from Invitrogen, Carlsbad, USA. Specific primers are listed in Online Supplementary Table 1 .
Colony-forming-cell assay
Sorted cells were seeded in methylcellulose (Methocult®-StemCell Tech). Colonies were scored at day 11 for AGM explant cultures and at day 10 or 14 for sorted cells.
Long-term culture-initiating cells assay (LTC-IC) and lymphoid switch
Serial half-dilutions of sorted cells were seeded over MS-5 stromal feeder cells in LTC-IC medium in 96-well microplates as previously described (10) . Cultures were maintained at 37°C with weekly half-medium changes. The frequency of cobblestone area forming cells (CAFC) and hematopoietic cells (HC) was determined on days 7 and 35 (LTC-IC) of culture using L-calc software (StemCell technologies). In some experiments, a lymphoid switch was performed at day 35. (13) Statistical analysis Mann-Whitney test was used to determine statistical significance. P values <0.05 were considered significant.
Results and Discussion
CD105 expression in the developing AGM
We analyzed mouse (E9 to E11) and human (30 days of gestation) AGM regions for CD105 expression during aortic hematopoiesis. CD105 was expressed by all vascular ECs of the mouse embryo as testified by the co-expression of CD105 with either CD144 or CD31 at E9, the earliest stage examined ( Figure 1A Figure 1) . On the E11 embryo, CD105 was expressed by most if not all vessels and by regions known to habour HSCs i.e. the fetal liver and the AGM ( Figure 1F ). In this latter, CD105 expression was restricted to endothelial and hematopoietic cell clusters attached to the endothelium confirming previous findings based on CD105 mRNA detection. (9) Immunohistology suggested the presence of variable levels of CD105 on mouse embryo hematopoietic clusters at E11 ( Figure  1G ). Interestingly, the same pattern was revealed on human embryo hematopoietic clusters ( Figure 1H ). Figure 3B ). Enrichment of CD105 int population in hematopoietic progenitors (HP) was comforted by the fact that it also presented a higher day 7 CAFC and HC frequency (3.4±1.8 and 3.8±0.9-fold respectively, n=3) than the CD105 hi population ( Figure 3C ). However, the LTC-IC potential was included in the CD105 hi population ( Figure 3C ), since day 35 CAFC frequency was at least 8 to 10-fold higher than in the CD105 int population (n=3)( Figure 3C ). Moreover, only CD105 hi population was able to produce B lymphoid cells after 35 days of coculture, with 86% of HC being B220 + CD19 + 10 days after the lymphoid switch (see Online Supplementary Figure 4A) , and was endowed with long-term reconstitution ability when injected into lethally-irradiated mice (Online Supplementary Figure 4B mRNA levels was also reported in long term vs short term HSCs in adult bone marrow.(6) Consistently, high levels of transcription factor or cell surface molecule expression, associated to immature hematopoietic progenitors or HSCs, have already been described in the bone marrow and in the AGM. (17, 18) Recently, a differential and spatial expression of CD41 (integrin GpIIb) has also been described. Contrary to CD105, the HSC potential was associated to the CD41 int population in the E11 AGM. (19) Interestingly, we observed that co-expression of CD105 with c-kit led to the identification of an AGM cell population harboring a strong clonogenic potential highly enriched in CFU-GM and immature CFU-Mix progenitors (Online Supplementary  Figure 3) . Whereas the frequency of CFU-GM and CFU-Mix within the c-kit + CD105 -populations is 1 for 652 and 1453 respectively, it reaches 1 for 64 for both in the ckit + CD105 + fraction (Online Supplementary Figure 3B ).
Most E11 AGM CD34
TGFb signaling regulates AGM hematopoietic activity
In line with the study of Marshall et al. on the human embryo (20) , RT-PCR analysis showed that CD105 + hematopoietic cells from the AGM expressed members of the TGFß signaling pathway, in particular TGFß1 ( Figure 3D and Supplementary Table1).
We then performed AGM explant cultures with or without soluble recombinant endoglin (sEnd) that prevents TGFb1-receptor binding. (21) Addition of sEnd increased the total number of clonogenic progenitors by 1.61 fold (control: 58.50±11.11; 500ng/ml sEnd: 94.50±7.42; p=0,001, n=3), demonstrating that downregulating the TGFß pathway increased the survival/growth of hematopoietic progenitors. As shown on Figure 3E , the strongest effects were seen on CFU-M and CFU-G (control: 42±8.12; sEnd: 66±6.38; control: 4.5±1.15; sEnd: 10.5±0.72, p=0.001, n=3, respectively), whereas no significant effect was observed on CFU-GM and CFU-Mix (control: 8 ±1.80; sEnd: 11±0.88; p=0.2; control: 4±1.60; sEnd: 7±3.28; p=0.35, n=3, respectively). These results point to the critical role of the TGFß pathway during AGM hematopoiesis, which negatively regulates the survival/growth of already committed AGM hematopoietic progenitors. Taken together these data place CD105 in the short list of molecules known to be differentially expressed in mature vs immature progenitors/HSCs and to exert a critical biological role in HPs/HSCs specification in the AGM. 
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A recipient mouse was considered positive when the percentage of reconstitution was above 5%.
